The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients / GIUSEPPE VISANI; MASSIMO BRECCIA; PIER PAOLO PICCALUGA; ANTONELLA GOZZINI; GIORGINA SPECCHIA; ENRICO MONTEFUSCO; ENRICA MORRA; MARIO ANNUNZIATA; LUIGIANA LUCIANO; ANDREA CAMERA; FRANCESCO CAVAZZINI; FABIO STAGNO; DI RAIMONDO F; PATRIZIA PREGNO; FRANCESCA PIRILLO; VALERIA SANTINI; ALBERTO BOSI; MATTEO PACILLI; ESTER PUNGOLINO; EMILIO USALA; EMANUELE ANGELUCCI; MONICA CRUGNOLA; GIANNI BINOTTO; ELENA MAINO; FEDERICA LOSCOCCO; SARA BARULLI; GIUSEPPINA NICOLINI; ANTONIO CUNEO; ROBERTO LATAGLIATA; FELICETTO FERRARA; AND ALESSANDRO ISIDORI. - (2009), pp. 1124-1124.
Titolo: | The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients |
Autori interni: | |
Data di pubblicazione: | 2009 |
Handle: | http://hdl.handle.net/20.500.11769/75923 |
Appare nelle tipologie: | 4.1 Contributo in Atti di convegno |